When.com Web Search

Search results

1. Results From The WOW.Com Content Network

2. A Boise clinic uses the drug ketamine to treat depression. Is ...

   www.aol.com/news/boise-clinic-uses-drug-ketamine...

   At the Boise Ketamine Clinic, the cost of ketamine is $350 per session in lozenge form, which is self-guided with monitoring from a nurse for 40 minutes to an hour, and $600 per session for ...

3. Huntsman Mental Health Institute - Wikipedia

   en.wikipedia.org/wiki/Huntsman_Mental_Health...

   The Huntsman Mental Health Institute (HMHI), formerly University Neuropsychiatric Institute (UNI), is an assemblage of psychiatric treatment, education, and research programs based in Salt Lake City, Utah. [1] [2] HMHI is a component of University of Utah Health Hospitals & Clinics. [3]

4. Ketamine-assisted psychotherapy - Wikipedia

   en.wikipedia.org/wiki/Ketamine-assisted...

   Ketamine-assisted psychotherapy (KAP) is the use of prescribed doses of ketamine as an adjunct to psychotherapy sessions. KAP shows significant potential in treating mental disorders such as treatment-resistant depression (TRD), anxiety, obsessive–compulsive disorders (OCD), post-traumatic stress disorders (PTSD), and other conditions. [1]

5. FDA approves Johnson & Johnson’s ketamine-derived ... - AOL

   www.aol.com/fda-approves-johnson-johnson...

   And now there’s a new option for treatment: Spravato, a nasal spray that’s been shown to give rapid relief to depression symptoms, was just approved as a stand-alone therapy by the Food and ...

6. Ketamine clinics for mental health are popping up across the ...

   www.aol.com/ketamine-clinics-mental-health...

   Inside Field Trip Health’s New York City clinic, the vibe is less doctor’s office, more tranquil spa.

7. Treatment-resistant depression - Wikipedia

   en.wikipedia.org/wiki/Treatment-resistant_depression

   Ketamine has been tested as a rapid-acting antidepressant [13] for treatment-resistant depression in bipolar disorder, and major depressive disorder. [14] Spravato, a nasal spray form of esketamine, was approved by the FDA in 2019 for use in treatment-resistant depression when combined with an oral antidepressant. [15] [16]